Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis

Trial Profile

Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Ruxolitinib (Primary) ; Busulfan; Filgrastim
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 16 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top